SEQSTER PDM Inc, the leading patient-centric healthcare technology company, announced a strategic partnership with Thread, a leading decentralized research and eCOA provider, to accelerate access to real-world data for patients, researchers and life science enterprises.
This partnership integrates primary data captured through Thread’s platform with instant access to secondary data from SEQSTER to expand the volume of participant data captured in a clinical research study. More combined data means an improved ability to determine the impact of new medicines, ultimately accelerating drug development. The partnership will also leverage Thread’s proprietary patient listening technology, ensuring that research studies with real-world data collection are designed with direct feedback from patients.
This solution is now available for biopharma and clinical research organization (CRO) clients to combine primary and secondary data for research. “Fragmentation of data for clinical research is a challenge for all research sponsors and we are excited to utilize this offering to support our clients,” said Aaron Berger, SVP of Evidence Development at UBC, “This partnership between THREAD and SEQSTER is an important step forward in improving the clinical research experience for sponsors, site staff and patients.”
“Real-time data turbocharges decision-making, giving researchers a rapid pulse on trends and potential pitfalls, as patient-first trial technology improves the research experience overall. Together, they empower researchers to optimize trial design and then efficiently deliver against that design,” stated Ardy Arianpour, CEO & Co-Founder of SEQSTER.
Access to patient medical records is an important part of research today, both to verify participant eligibility for research and to serve as evidence for demonstrating efficacy and safety of an intervention.
“Our partnership with SEQSTER is impactful for both patients and researchers. By enabling real-time medical record access integrated with Thread’s platform, we simplify the research experience and provide access to more data,” said John Reites, Co-founder, CEO of Thread.
SOURCE: Businesswire